FDA Extends Roflumilast’s AD Approval to Young Children



The approval is for children ages 2-5 with mild-to-moderate atopic dermatitis.
Medscape Medical News



Source link : https://www.medscape.com/viewarticle/fda-extends-topical-roflumilasts-atopic-dermatitis-approval-2025a1000quo?src=rss

Author :

Publish date : 2025-10-06 20:11:00

Copyright for syndicated content belongs to the linked Source.
Exit mobile version